• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同严重程度慢性阻塞性肺疾病患者肠道微生物群的综合分析——一项前瞻性观察性研究

Comprehensive analysis of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity-A prospective, observational study.

作者信息

Yan Jiali, Wu Zhenhu, Deng Li, Huang Chunzhen, Jing Yuting, Chen Xiao-Yin, Xu Yinji

机构信息

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510403, Guangdong Province, China.

出版信息

Heliyon. 2024 May 19;10(11):e31512. doi: 10.1016/j.heliyon.2024.e31512. eCollection 2024 Jun 15.

DOI:10.1016/j.heliyon.2024.e31512
PMID:38845997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11153110/
Abstract

Accumulating evidence has highlighted the influence of the gut microbiota on lung immunity. We examined the effects of changes in intestinal microecology on the development of Chronic Obstructive Pulmonary Disease (COPD) and identified microbial biomarkers for acute exacerbations of COPD (AECOPD). Fecal samples were collected from 30 patients with stable COPD, 30 patients with AECOPD, and 10 healthy individuals. Fecal microbiological profiles were analyzed using 16S rRNA gene sequencing. The results showed a distinct difference in the bacterial community composition between the AECOPD, COPD, and healthy control groups. The COPD and AECOPD groups had higher levels of Firmicutes but lower levels of Bacteroidetes compared to the healthy control group at the phylum level. At the genus level, there was an increased abundance of Lachnoclostridium, Alistipes, Streptococcus, and Prevotella in COPD and AECOPD patients. Increasing levels of Lachnoclostridium and Prevotella may indicate an acute exacerbation of COPD. This study identified specific microbial biomarkers associated with AECOPD and characterized the composition of gut microbiota in patients with AECOPD.

摘要

越来越多的证据凸显了肠道微生物群对肺部免疫的影响。我们研究了肠道微生态变化对慢性阻塞性肺疾病(COPD)发展的影响,并确定了慢性阻塞性肺疾病急性加重(AECOPD)的微生物生物标志物。收集了30例稳定期COPD患者、30例AECOPD患者和10名健康个体的粪便样本。使用16S rRNA基因测序分析粪便微生物谱。结果显示,AECOPD组、COPD组和健康对照组之间的细菌群落组成存在明显差异。在门水平上,与健康对照组相比,COPD组和AECOPD组的厚壁菌门水平较高,而拟杆菌门水平较低。在属水平上,COPD和AECOPD患者中毛螺菌属、艾氏菌属、链球菌属和普雷沃菌属的丰度增加。毛螺菌属和普雷沃菌属水平的升高可能表明COPD急性加重。本研究确定了与AECOPD相关的特定微生物生物标志物,并对AECOPD患者的肠道微生物群组成进行了特征分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/36799cc5e8e8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/742d6f4c493e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/56067cce9fe6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/853b9094e610/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/4be2e87c8859/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/7d4a1d23c52c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/36799cc5e8e8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/742d6f4c493e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/56067cce9fe6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/853b9094e610/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/4be2e87c8859/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/7d4a1d23c52c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b87/11153110/36799cc5e8e8/gr6.jpg

相似文献

1
Comprehensive analysis of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity-A prospective, observational study.不同严重程度慢性阻塞性肺疾病患者肠道微生物群的综合分析——一项前瞻性观察性研究
Heliyon. 2024 May 19;10(11):e31512. doi: 10.1016/j.heliyon.2024.e31512. eCollection 2024 Jun 15.
2
Variations in fecal microbial profiles of acute exacerbations and stable chronic obstructive pulmonary disease.急性加重期和稳定期慢性阻塞性肺疾病粪便微生物特征的变化。
Life Sci. 2021 Jan 15;265:118738. doi: 10.1016/j.lfs.2020.118738. Epub 2020 Nov 10.
3
Characteristics of the sputum microbiome in COPD exacerbations and correlations between clinical indices.COPD 加重期痰液微生物组特征及其与临床指标的相关性。
J Transl Med. 2022 Feb 5;20(1):76. doi: 10.1186/s12967-022-03278-x.
4
Analysis of the correlation between BMI and respiratory tract microbiota in acute exacerbation of COPD.分析 BMI 与 COPD 急性加重期呼吸道微生物群的相关性。
Front Cell Infect Microbiol. 2023 Apr 25;13:1161203. doi: 10.3389/fcimb.2023.1161203. eCollection 2023.
5
Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state.慢性阻塞性肺疾病患者临床稳定期痰液微生物组与加重表型的相关性研究。
J Transl Med. 2021 Mar 23;19(1):121. doi: 10.1186/s12967-021-02788-4.
6
Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations.慢性阻塞性肺疾病恶化过程中肠道和肺部微生物的动态变化。
Kaohsiung J Med Sci. 2020 Feb;36(2):107-113. doi: 10.1002/kjm2.12147. Epub 2019 Nov 29.
7
Lung Mycobiota α-Diversity Is Linked to Severity in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.肺部真菌群的α多样性与慢性阻塞性肺疾病急性加重期重症患者的病情严重程度相关。
Microbiol Spectr. 2023 Mar 28;11(2):e0506222. doi: 10.1128/spectrum.05062-22.
8
Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis.慢性阻塞性肺疾病患者与健康个体的肺部微生物群组成及支气管上皮基因表达:细菌16S rRNA基因测序和宿主转录组分析
Lancet Microbe. 2021 Jul;2(7):e300-e310. doi: 10.1016/S2666-5247(21)00035-5. Epub 2021 Apr 23.
9
The altered sputum microbiome profile in patients with moderate and severe COPD exacerbations, compared to the healthy group in the Indian population.与健康人群相比,印度人群中中度和重度 COPD 加重患者的痰液微生物组谱发生了改变。
F1000Res. 2023 Oct 27;12:528. doi: 10.12688/f1000research.132220.3. eCollection 2023.
10
Long non-coding RNA PVT1, a novel biomarker for chronic obstructive pulmonary disease progression surveillance and acute exacerbation prediction potentially through interaction with microRNA-146a.长链非编码RNA PVT1,一种可能通过与微小RNA-146a相互作用来监测慢性阻塞性肺疾病进展和预测急性加重的新型生物标志物。
J Clin Lab Anal. 2020 Aug;34(8):e23346. doi: 10.1002/jcla.23346. Epub 2020 Apr 27.

引用本文的文献

1
Chronic obstructive pulmonary disease: in-depth analysis of microbiota association and innovative prevention and treatment approaches from the gut-lung axis perspective.慢性阻塞性肺疾病:从肠-肺轴角度对微生物群关联及创新防治方法的深入分析
Front Immunol. 2025 Jul 30;16:1549865. doi: 10.3389/fimmu.2025.1549865. eCollection 2025.
2
Genetic prediction of immune cells, inflammatory proteins, and metabolite-mediated association between gut microbiota and COPD: a Mendelian randomization study.免疫细胞、炎症蛋白以及肠道微生物群与慢性阻塞性肺疾病之间代谢物介导关联的遗传预测:一项孟德尔随机化研究
Sci Rep. 2025 Jul 1;15(1):21633. doi: 10.1038/s41598-025-05290-9.
3

本文引用的文献

1
Enterococcus spp. and Streptococcus spp. bloodstream infections: epidemiology and therapeutic approach.肠球菌属和链球菌属血流感染:流行病学和治疗方法。
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):2-4. doi: 10.37201/req/s01.01.2023. Epub 2023 Nov 24.
2
The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin.F/B 比值作为 COVID-19 和 T2D 炎症的生物标志物:二甲双胍的影响。
Biomed Pharmacother. 2023 Jul;163:114892. doi: 10.1016/j.biopha.2023.114892. Epub 2023 May 15.
3
Contemporary Concise Review 2022: Chronic obstructive pulmonary disease.
Characterizing gut microbial dysbiosis and exploring the effect of prebiotic fiber supplementation in patients with COPD.
表征慢性阻塞性肺疾病(COPD)患者的肠道微生物失调并探索补充益生元纤维的效果。
Eur J Nutr. 2025 Jun 7;64(5):210. doi: 10.1007/s00394-025-03733-7.
4
Lung Microbiota: From Healthy Lungs to Development of Chronic Obstructive Pulmonary Disease.肺微生物群:从健康肺脏到慢性阻塞性肺疾病的发展
Int J Mol Sci. 2025 Feb 7;26(4):1403. doi: 10.3390/ijms26041403.
5
The role and mechanism of gut-lung axis mediated bidirectional communication in the occurrence and development of chronic obstructive pulmonary disease.肠-肺轴介导的双向通讯在慢性阻塞性肺疾病发生发展中的作用及其机制。
Gut Microbes. 2024 Jan-Dec;16(1):2414805. doi: 10.1080/19490976.2024.2414805. Epub 2024 Oct 24.
《2022年当代简明综述:慢性阻塞性肺疾病》
Respirology. 2023 May;28(5):428-436. doi: 10.1111/resp.14489. Epub 2023 Mar 15.
4
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告:《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
5
The gut microbiome is a significant risk factor for future chronic lung disease.肠道微生物组是未来慢性肺部疾病的重要危险因素。
J Allergy Clin Immunol. 2023 Apr;151(4):943-952. doi: 10.1016/j.jaci.2022.12.810. Epub 2022 Dec 29.
6
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory lipopolysaccharide.肠道微生物群调节慢性阻塞性肺疾病的发病机制:抗炎脂多糖的作用。
Gut. 2022 Feb;71(2):309-321. doi: 10.1136/gutjnl-2020-322599. Epub 2021 Mar 9.
7
Advances in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病进展。
Annu Rev Med. 2021 Jan 27;72:119-134. doi: 10.1146/annurev-med-080919-112707.
8
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals.1098 名深度表型个体的微生物组与宿主代谢和习惯性饮食的关联。
Nat Med. 2021 Feb;27(2):321-332. doi: 10.1038/s41591-020-01183-8. Epub 2021 Jan 11.
9
Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的疾病相关肠道微生物组和代谢组变化。
Nat Commun. 2020 Nov 18;11(1):5886. doi: 10.1038/s41467-020-19701-0.
10
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease.益生菌对肥胖症和炎症性肠病治疗中厚壁菌门/拟杆菌门比例的影响
Microorganisms. 2020 Nov 1;8(11):1715. doi: 10.3390/microorganisms8111715.